Treatment allocation
visual improvements
Each study eye was randomised by the unmasked research officer to either the experimental group “combination therapy” with TPRP and aflibercept, or the active control group “aflibercept monotherapy”. In patients with both eyes eligible for the study, the eyes were randomised to have different therapies.Stratification to the treatments was carried out to include equal proportions of patients with BCVA less than 70 LogMAR letters at entry to the study. This stratification was inferred from outcomes of DRCRnet Protocol T where participants with worse starting vision had larger visual improvements [